Skip to content
Peptigraph home
Shop Peptides50% off*

How to Inject Kisspeptin-10: Sites, Syringes and Steps

Where to inject Kisspeptin-10, which syringe to use, how to read units and the hygiene steps that prevent infection.

Medical review pendingGnRH stimulatorUpdated
This is a general guide to subcutaneous injection, not a substitute for being shown by a nurse, pharmacist or doctor.

Injection sites

Most peptides are injected under the skin (subcutaneously), into the fatty layer rather than the muscle.

  • Belly: at least 2 inches (5 cm) away from the navel.
  • Front and outer thighs.
  • Back of the upper arms, if someone else can reach it.
  • Rotate sites each time and avoid skin that is bruised, scarred or irritated.

Syringe and needle

U-100 insulin syringes are marked in units: 100 units equal 1 mL, so 10 units is 0.1 mL. They come in 0.3, 0.5 and 1 mL sizes; a smaller syringe has finer marks and is easier to read for small doses. Needle length and gauge used for Kisspeptin-10 in studies: not reported in study abstracts (PubMed search, 11 Oct 2026).

How to read an insulin syringe

Step by step

  1. 1Wash your handsUse soap and water, and work on a clean surface.
  2. 2Check the vialLabel, lot and date present; solution clear with no particles. Mixing a powder vial first? Use sterile bacteriostatic water.
  3. 3Clean the vial top and the siteWipe both with an alcohol swab and let them dry.
  4. 4Draw the dosePull the plunger to the units mark for your dose, then tap out air bubbles and re-check the mark.
  5. 5InjectPinch a fold of skin, insert the needle at 45 to 90 degrees, push the plunger slowly and wait a few seconds before withdrawing.
  6. 6Dispose safelyPut the used syringe straight into a sharps container. Never reuse or share needles.
How to reconstitute a peptide vial

Routes and schedules used in the human studies

Healthy men received kisspeptin-10 as a subcutaneous infusion, with acute dose-response and chronic regimens.[12]

One study compared intravenous bolus kisspeptin-10 in men and women, and added subcutaneous bolus and intravenous infusion arms in women.[13]

The kisspeptin-54 study in female volunteers used a subcutaneous bolus.[14]

The repeat-dosing study used twice-daily subcutaneous injections for 2 weeks.[15]

An 8-week study used twice-weekly kisspeptin-54 injections in the same condition.[16]

A growth hormone safety study gave kisspeptin-54 as a twice-daily subcutaneous bolus for 7 days.[17]

An IVF study gave kisspeptin-54 as a single subcutaneous injection after ovarian stimulation.[18]

What the sources do not state

None of the 10 cached kisspeptin abstracts quoted for routes names an anatomical injection site, so no body site is cited for any route.

Calculated from abstracts checked 42549827, 21976724, 17635940, 19820030, 20980998, 25036713, 37925096, 24863252, 31820802, 21632807; naming an anatomical site 0. Formula: count of listed abstracts containing abdomen, thigh, arm, buttock, deltoid or injection-site wording = 0

No labelled administration steps exist, since the Drugs@FDA search for the ingredient returned no matches.[19]

Common questions

Where do you inject Kisspeptin-10?

Under-the-skin (subcutaneous) injections are usually given in the belly, at least 2 inches from the navel, the front of the thighs or the back of the upper arms. Rotate sites each time.

What syringe is used for Kisspeptin-10?

Vials are usually drawn with a U-100 insulin syringe, where 100 units equal 1 mL. Common sizes hold 0.3, 0.5 or 1 mL. Match the syringe to the dose so the mark is easy to read.

How often is Kisspeptin-10 injected?

The interval comes from the study or prescription, not from this guide. See the dosage page for what studies used.

Where do you inject kisspeptin?

The cached studies state the route (subcutaneous or intravenous) but not the body site; the analog MVT-602 trials also give single subcutaneous doses.[20]

More on Kisspeptin-10

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.BenefitsClaimed benefits next to what published studies measured.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  2. 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3PubMed search: ("kisspeptin-10"[tiab] OR "kisspeptin 10"[tiab]) AND humans[mh] (110 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  4. 4PubMed search: (kisspeptin[tiab]) AND humans[mh] AND (randomized controlled trial[pt] OR clinical trial[pt]) (54 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  5. 5PubMed search: kisspeptin[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) AND humans[mh] (13 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  6. 6PubMed search: kisspeptin[tiab] AND humans[mh] AND (men[tiab] OR male[tiab]) AND (testosterone[tiab] OR hypogonadism[tiab]) (90 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7PubMed search: kisspeptin[tiab] AND (menopaus*[tiab] OR postmenopaus*[tiab]) (89 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: kisspeptin[tiab] AND (liver[tiab] OR NAFLD[tiab] OR hepatic[tiab]) (68 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: ("kisspeptin-10"[tiab] OR "kisspeptin-54"[tiab] OR kisspeptin[tiab]) AND humans[mh] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (75 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  10. 10PubMed search: (kisspeptin[tiab]) AND (nausea[tiab] OR flush*[tiab] OR "injection site"[tiab] OR headache[tiab] OR "ovarian hyperstimulation"[tiab] OR tachyphylaxis[tiab] OR desensiti*[tiab]) AND humans[mh] (60 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  11. 11PubMed search: (kisspeptin[tiab] OR "kisspeptin-54"[tiab] OR "kisspeptin-10"[tiab]) AND ("clinical trial"[pt] OR "randomized controlled trial"[pt]) AND (women[tiab] OR men[tiab]) AND (adverse[tiab] OR tolerat*[tiab] OR "side effects"[tiab]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  12. 12Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men.European journal of endocrinology · 2026PMID 42549827Accessed 2 Oct 2026
  13. 13The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans.The Journal of clinical endocrinology and metabolism · 2011PMID 21976724Accessed 2 Oct 2026
  14. 14Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women.The Journal of clinical endocrinology and metabolism · 2007PMID 17635940Accessed 2 Oct 2026
  15. 15Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis.The Journal of clinical endocrinology and metabolism · 2009PMID 19820030Accessed 2 Oct 2026
  16. 16Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea.Clinical pharmacology and therapeutics · 2010PMID 20980998Accessed 2 Oct 2026
  17. 17Acute and chronic effects of kisspeptin-54 administration on GH, prolactin and TSH secretion in healthy women.Clinical endocrinology · 2014PMID 24863252Accessed 2 Oct 2026
  18. 18Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.The Journal of clinical investigation · 2014PMID 25036713Accessed 2 Oct 2026
  19. 19Drugs@FDA (openFDA) search: active ingredient "kisspeptin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  20. 20Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals.Fertility and sterility · 2024PMID 37925096Accessed 2 Oct 2026

Found an error? Report a correction.